Rocco Piazza

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9191590/publications.pdf

Version: 2024-02-01

112 papers	4,183 citations	201385 27 h-index	118652 62 g-index
116 all docs	116 docs citations	116 times ranked	5598 citing authors

#	Article	IF	Citations
1	Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants. Journal of Clinical Oncology, 2009, 27, 469-471.	0.8	365
2	Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib. Journal of the National Cancer Institute, 2011, 103, 553-561.	3.0	362
3	Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nature Genetics, 2013, 45, 18-24.	9.4	359
4	In vitro and In vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells. Cancer Research, 2006, 66, 11314-11322.	0.4	352
5	Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncology, The, 2003, 4, 75-85.	5.1	349
6	Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinaseâ€“Positive Lymphoma Patients. Journal of the National Cancer Institute, 2014, 106, djt378.	3.0	207
7	Age and d<scp>PCR</scp> can predict relapse in <scp>CML</scp> patients who discontinued imatinib: The <scp>ISAV</scp> study. American Journal of Hematology, 2015, 90, 910-914.	2.0	181
8	A diastrophic dysplasia sulfate transporter (SLC26A2) mutant mouse: morphological and biochemical characterization of the resulting chondrodysplasia phenotype. Human Molecular Genetics, 2005, 14, 859-871.	1.4	116
9	Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood, 2015, 125, 499-503.	0.6	115
10	Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood, 2010, 116, 3013-3022.	0.6	110
11	Three novel patientâ€derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. American Journal of Hematology, 2012, 87, E125-8.	2.0	93
12	Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: AÂsystematic review and a meta-analysis. European Journal of Cancer, 2017, 77, 48-56.	1.3	74
13	Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer. Cancer Research, 2018, 78, 6866-6880.	0.4	69
14	SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. Nature Communications, 2018, 9, 2192.	5.8	66
15	Mutational signatures and heterogeneous host response revealed via large-scale characterization of SARS-CoV-2 genomic diversity. IScience, 2021, 24, 102116.	1.9	64
16	In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nature Medicine, 2007, 13, 13-14.	15.2	54
17	Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALKâ€“Positive Anaplastic Large Cell Lymphoma. Molecular Cancer Research, 2015, 13, 775-783.	1.5	52
18	Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex. Neoplasia, 2013, 15, 511-IN17.	2.3	44

#	Article	IF	Citations
19	Gene expression signature of non-involved lung tissue associated with survival in lung adenocarcinoma patients. Carcinogenesis, 2013, 34, 2767-2773.	1.3	40
20	BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients. Leukemia, 2010, 24, 1445-1449.	3.3	37
21	Clinical relevance of clonal hematopoiesis in persons aged â‰¥80 years. Blood, 2021, 138, 2093-2105.	0.6	37
22	BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene. Molecular Cancer, 2015, 14, 132.	7.9	35
23	NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma. Blood, 2007, 110, 2600-2609.	0.6	34
24	Chronic myeloid leukemia: Secondâ€line drugs of choice. American Journal of Hematology, 2016, 91, 67-75.	2.0	33
25	OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes. Scientific Reports, 2017, 7, 46290.	1.6	31
26	NKG2A expression identifies a subset of human VÎ2 TÂcells exerting the highest antitumor effector functions. Cell Reports, 2021, 37, 109871.	2.9	30
27	Valproic acid enhances bosutinib cytotoxicity in colon cancer cells. International Journal of Cancer, 2009, 124, 1990-1996.	2.3	29
28	FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery. Nucleic Acids Research, 2012, 40, e123-e123.	6.5	29
29	NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922. Oncotarget, 2015, 6, 5720-5734.	0.8	29
30	EXT 1 Gene Mutation Induces Chondrocyte Cytoskeletal Abnormalities and Defective Collagen Expression in the Exostoses. Journal of Bone and Mineral Research, 2000, 15, 1489-1500.	3.1	28
31	The role of bosutinib in the treatment of chronic myeloid leukemia. Future Oncology, 2020, 16, 4395-4408.	1.1	26
32	Absent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin-interacting protein 1 deficiency. Blood, 2021, 137, 493-499.	0.6	26
33	VERSO: A comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples. Patterns, 2021, 2, 100212.	3.1	26
34	ERG Deregulation Induces PIM1 Over-Expression and Aneuploidy in Prostate Epithelial Cells. PLoS ONE, 2011, 6, e28162.	1.1	25
35	Firstâ€line treatment of 102 chronic myeloid leukemia patients with imatinib: A longâ€term single institution analysis. American Journal of Hematology, 2014, 89, E184-7.	2.0	24
36	SETBP1 accumulation induces P53 inhibition and genotoxic stress in neural progenitors underlying neurodegeneration in Schinzel-Giedion syndrome. Nature Communications, 2021, 12, 4050.	5.8	24

#	Article	IF	Citations
37	A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib. Journal of Thoracic Oncology, 2019, 14, e257-e259.	0.5	23
38	ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine. Nature Communications, 2020, 11, 5938.	5.8	22
39	De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways. Haematologica, 2019, 104, 1789-1797.	1.7	21
40	Phase two study of crizotinib in patients with anaplastic lymphoma kinase (<scp>ALK</scp>)â€positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy. American Journal of Hematology, 2020, 95, E319-E321.	2.0	21
41	CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data. PLoS ONE, 2013, 8, e74825.	1.1	20
42	In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib. Journal of Hematology and Oncology, 2015, 8, 81.	6.9	20
43	Morgana acts as an oncosuppressor in chronic myeloid leukemia. Blood, 2015, 125, 2245-2253.	0.6	19
44	14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T and myeloid immature acute leukemia. Blood, 2021, 138, 773-784.	0.6	19
45	How <scp>I</scp> treat newly diagnosed chronic myeloid leukemia in 2015. American Journal of Hematology, 2015, 90, 156-161.	2.0	18
46	Identification of novel point mutations in splicing sites integrating wholeâ€exome and <scp>RNA</scp>â€seq data in myeloproliferative diseases. Molecular Genetics & Genomic Medicine, 2013, 1, 246-259.	0.6	17
47	Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels. Blood, 2003, 102, 1933-1935.	0.6	16
48	Bosutinib: a review of preclinical and clinical studies in chronic myelogenous leukemia. Expert Opinion on Pharmacotherapy, 2014, 15, 701-710.	0.9	16
49	Imatinibâ€”A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015. JAMA Oncology, 2015, 1, 143.	3.4	16
50	Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes ÎºBÎ± mediated p53 nuclear exclusion. Oncotarget, 2015, 6, 25217-25225.	0.8	16
51	Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib. Leukemia, 2005, 19, 132-134.	3.3	15
52	Read-through transcripts in normal human lung parenchyma are down-regulated in lung adenocarcinoma. Oncotarget, 2016, 7, 27889-27898.	0.8	15
53	An Optimal Control Framework for the Automated Design of Personalized Cancer Treatments. Frontiers in Bioengineering and Biotechnology, 2020, 8, 523.	2.0	15
54	Large-scale analysis of SARS-CoV-2 synonymous mutations reveals the adaptation to the human codon usage during the virus evolution. Virus Evolution, 2022, 8, veac026.	2.2	15

#	Article	IF	Citations
55	Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia. HemaSphere, 2020, 4, e497.	1.2	14
56	LACE: Inference of cancer evolution models from longitudinal single-cell sequencing data. Journal of Computational Science, 2022, 58, 101523.	1.5	14
57	Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients. American Journal of Hematology, 2017, 92, E623-E625.	2.0	13
58	Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells. Neoplasia, 2018, 20, 467-477.	2.3	13
59	Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation. Blood, 2020, 136, 2237-2240.	0.6	13
60	Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success. American Journal of Hematology, 2022, 97, 1075-1085.	2.0	13
61	Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma. Cancers, 2021, 13, 4422.	1.7	11
62	High Response Rates To Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients. Blood, 2013, 122, 368-368.	0.6	10
63	Imatinib dose increase up to 1200â€‰mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients. Leukemia, 2005, 19, 1985-1987.	3.3	9
64	The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years. Blood Cells, Molecules, and Diseases, 2006, 37, 111-115.	0.6	9
65	IN VITRO PROTEOGLYCAN SULFATION DERIVED FROM SULFHYDRYL COMPOUNDS IN SULFATE TRANSPORTER CHONDRODYSPLASIAS. Fetal and Pediatric Pathology, 2003, 22, 311-321.	0.3	8
66	Choosing the right TKI for chronic myeloid leukemia: When the truth lies in â€œlongâ€termâ€•safety and efficacy. American Journal of Hematology, 2011, 86, 531-532.	2.0	8
67	A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation. Leukemia Research, 2020, 97, 106441.	0.4	8
68	Imatinib Suspension and Validation (ISAV) Study: Final Results at 79 Months. Blood, 2018, 132, 461-461.	0.6	8
69	CD24/Siglec-10 "Don't Eat Me" Signal Blockade Is a Potential Immunotherapeutic Target in Mantle-Cell Lymphoma. Blood, 2021, 138, 2276-2276.	0.6	8
70	Reply to P. Laneuville et al. Journal of Clinical Oncology, 2010, 28, e172-e172.	0.8	7
71	How â€œpreciseâ€•is precision medicine in hematology?. Haematologica, 2017, 102, 4-6.	1.7	7
72	Development of c-Kit-expressing Small-Cell Lung Cancer in a Chronic Myeloid Leukemia Patient During Imatinib Treatment. Journal of the National Cancer Institute, 2004, 96, 1723-1724.	3.0	5

#	Article	IF	Citations
73	Case Report: Hypomorphic Function and Somatic Reversion in DOCK8 Deficiency in One Patient With Two Novel Variants and Sclerosing Cholangitis. Frontiers in Immunology, 2021, 12, 673487.	2.2	5
74	HIF1A: A Putative Modifier of Hemochromatosis. International Journal of Molecular Sciences, 2021, 22, 1245.	1.8	5
75	Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia. Frontiers in Oncology, 2021, 11, 756348.	1.3	5
76	Variant calling from scRNA-seq data allows the assessment of cellular identity in patient-derived cell lines. Nature Communications, 2022, 13, 2718.	5.8	5
77	Insights from a Transgenic Mouse Model on the Role of SLC26A2 in Health and Disease. Novartis Foundation Symposium, 2008, , 193-212.	1.2	4
78	A distinct epigenetic program underlies the 1;7 translocation in myelodysplastic syndromes. Leukemia, 2019, 33, 2481-2494.	3.3	4
79	Identification of genetic polymorphisms modulating nausea and vomiting in two series of opioid-treated cancer patients. Scientific Reports, 2020, 10, 542.	1.6	4
80	The Giant HECT E3 Ubiquitin Ligase HERC1 Is Aberrantly Expressed in Myeloid Related Disorders and It Is a Novel BCR-ABL1 Binding Partner. Cancers, 2021, 13, 341.	1.7	4
81	IN VITRO PROTEOGLYCAN SULFATION DERIVED FROM SULFHYDRYL COMPOUNDS IN SULFATE TRANSPORTER CHONDRODYSPLASIAS. Fetal and Pediatric Pathology, 2003, 22, 311-321.	0.3	4
82	The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis. Blood, 2014, 124, 813-813.	0.6	4
83	Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling. Cancers, 2018, 10, 509.	1.7	3
84	APOL1 polymorphism modulates sphingolipid profile of human podocytes. Glycoconjugate Journal, 2020, 37, 729-744.	1.4	3
85	Impact of ETNK1 somatic mutations on phosphoethanolamine synthesis, ROS production and DNA damage. Molecular and Cellular Oncology, 2021, 8, 1877598.	0.3	3
86	Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies. Transfusion and Apheresis Science, 2021, 60, 103105.	0.5	3
87	Imatinib Suspension and Validation (ISAV) Study: Results at 24 Months. Blood, 2015, 126, 2775-2775.	0.6	3
88	VirMutSig: Discovery and assignment of viral mutational signatures from sequencing data. STAR Protocols, 2021, 2, 100911.	0.5	3
89	RNAâ€seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients. American Journal of Hematology, 2015, 90, E227-8.	2.0	2
90	Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL). Hematological Oncology, 2019, 37, 505-507.	0.8	2

#	Article	IF	Citations
91	Germâ€Line TP53ÂMutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition. HemaSphere, 2020, 4, e460.	1.2	2
92	Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR. Blood, 2019, 134, 29-29.	0.6	2
93	BCR and BCR/ABL Regulation during Myeloid Differentiation in Healthy Donors and in Chronic Phase/Blast Crisis CML Patients. Blood, 2008, 112, 3204-3204.	0.6	2
94	Insights from a transgenic mouse model on the role of SLC26A2 in health and disease. Novartis Foundation Symposium, 2006, 273, 193-206; discussion 206-12, 261-4.	1.2	2
95	Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia. American Journal of Hematology, 2022, 97, .	2.0	2
96	Response to â€˜D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patientsâ€™ by Leguay et al. Leukemia, 2005, 19, 2333-2334.	3.3	1
97	An Imatinibâ€“nonâ€responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization. Clinical Case Reports (discontinued), 2020, 8, 71-74.	0.2	1
98	Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia. Blood, 2012, 120, 3727-3727.	0.6	1
99	Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis. Blood, 2016, 128, 3075-3075.	0.6	1
100	Highly Sensitive Mutations Detection in BCR-ABL Positive Leukemia Prior and during Imatinib Treatment.. Blood, 2004, 104, 1985-1985.	0.6	1
101	SETBP1 and CSF3R Mutations In Atypical Chronic Myeloid Leukemia. Blood, 2013, 122, 2598-2598.	0.6	1
102	ETNK1 Is an Early Event and SETBP1 a Late Event in Atypical Chronic Myeloid Leukemia. Blood, 2015, 126, 3652-3652.	0.6	1
103	ETNK1 Mutations in Atypical Chronic Myeloid Leukemia Induce a Mutator Phenotype That Can be Reverted with Phosphoethanolamine. Blood, 2020, 136, LBA-5-LBA-5.	0.6	1
104	A Bioinformatics Procedure to Identify and Annotate Somatic Mutations in Whole-Exome Sequencing Data. Lecture Notes in Computer Science, 2012, , 73-82.	1.0	0
105	Whole-Exome Sequencing Data â€“ Identifying Somatic Mutations. , 2014, , 419-427.		0
106	Human Chromosome 18 and Acrocentrics: A Dangerous Liaison. International Journal of Molecular Sciences, 2021, 22, 5637.	1.8	0
107	Determination of the Activity Profile of Bosutinib, Dasatinib and Nilotinib against 18 Imatinib Resistant Bcr/Abl Mutants. Blood, 2008, 112, 3220-3220.	0.6	0
108	Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years,. Blood, 2011, 118, 3766-3766.	0.6	0

#	Article	IF	Citations
109	CML Patients Present Additional Mutations in Cancer Related Genes When Tested At Diagnosis. Blood, 2011, 118, 2739-2739.	0.6	0
110	Validation of Digital-PCR Analysis through Programmed imatinib Interruption in Q-RT-PCR Negative Chronic Myeloid Leukemia Patients. Blood, 2013, 122, 4040-4040.	0.6	0
111	Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients. Blood, 2019, 134, 1714-1714.	0.6	0
112	Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience. Leukemia Research, 2022, 118, 106861.	0.4	0